Amylyx Pharmaceuticals, Inc.

Cambridge-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) develops clinical-stage therapeutics for rare endocrine and neurodegenerative conditions. Its lead asset, Avexitide, is a first-in-class GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism.

The company’s pipeline also features AMX0035 in mid-to-late-stage trials for progressive supranuclear palsy and Wolfram syndrome, alongside AMX0114 for ALS and AMX0318 for rare metabolic disorders.